KEY POINTS
- This practical review from Allegheny Health Network Cancer Institute addresses modern hybrid intracavitary–interstitial brachytherapy (HBT) and interstitial brachytherapy (ISBT) for locally advanced cervical and vaginal cancers. Its focus is applicator selection, procedural safety, imaging, target delineation, dose optimization, toxicity prevention, and competency requirements. HBT combines conventional intracavitary applicators with interstitial needles, allowing improved coverage of asymmetric or extensive residual tumor while limiting unnecessary OAR exposure.
- Hybrid brachytherapy is particularly relevant when standard intracavitary geometry cannot adequately cover residual disease. Common indications include asymmetric targets even when HR-CTV <30 cm³, bulky residual tumors with HR-CTV >30 cm³, parametrial extension, and paravaginal or vaginal involvement. Modern straight and oblique needle configurations can extend the prescription-dose region approximately 3–4 cm laterally from the tandem, depending on applicator design. More extensive lateral disease, distal vaginal involvement, or distorted anatomy may require template-based ISBT.
- Image guidance is essential for safe applicator placement and accurate target delineation. Transabdominal or transrectal ultrasound can guide tandem insertion and reduce uterine perforation risk, while Doppler imaging may help avoid vascular injury during needle placement. Postimplant MRI is preferred for target and OAR delineation, particularly using T2-weighted sequences; CT-based planning informed by prebrachytherapy MRI remains an alternative where MRI access is limited. The review emphasizes individualized applicator selection based on post-EBRT tumor response and anatomy.
- Cervical cancer dose planning is based on cumulative EBRT plus brachytherapy EQD2. The review summarizes planning aims of HR-CTV D90% >85 Gy EQD2₁₀, ideally >90–95 Gy, with HR-CTV D98% >75 Gy and GTVres D98% >90 Gy. After 45 Gy in 25 fractions of external-beam RT, common HDR prescriptions include 8 Gy × 3, 7 Gy × 4, or 6 Gy × 5 fractions, corresponding to nominal cumulative EQD2₁₀ values of approximately 80.3, 83.9, and 84.3 Gy, respectively. Additional dose optimization is generally needed to reach the higher HR-CTV D90% planning goals.
- Organ-at-risk constraints are central to adaptive brachytherapy optimization. Recommended cumulative D2cm³ goals expressed as EQD2₃ include bladder <80 Gy, rectum <65 Gy, small bowel <65 Gy, and sigmoid <70 Gy. The respective maximum limits summarized in the review are 85 Gy for bladder and 75 Gy for rectum, small bowel, and sigmoid. Bladder filling, needle position, dwell-time distribution, and applicator geometry must be evaluated together, because improving dose to one organ may worsen exposure to another.
- Treatment duration and procedural management affect overall treatment quality. The review recommends completing EBRT and brachytherapy within approximately 50 days, with prolonged treatment potentially requiring greater biological dose to maintain comparable tumor control. Hybrid brachytherapy may use repeated implants or a single implant with multiple fractions, while more extensive ISBT commonly involves hospitalization and several fractions over consecutive days. Common procedure-related complications include vaginal bleeding after needle removal, reported in approximately 5–25% of patients in cited series, and inadvertent needle placement into adjacent organs, emphasizing the importance of image guidance and procedural QA.
- The article highlights training and standardization rather than generating new efficacy evidence. Available hybrid and interstitial applicators vary in geometry, MRI compatibility, and needle trajectories, requiring procedural expertise and reliable multidisciplinary support. Brachytherapy training opportunities remain inconsistent across residency programs, and not all centers can provide sufficient hands-on experience. The article therefore advocates standardized training in applicator selection, imaging, cumulative EQD2 evaluation, and complication management rather than proposing a new treatment regimen or replacing established consensus guidelines.
CLINICAL TAKEAWAY
Hybrid and interstitial HDR brachytherapy are important tools for achieving adequate target coverage while respecting OAR constraints in locally advanced cervical and vaginal cancers. This review provides practical guidance on when to escalate beyond standard intracavitary techniques and how to implement image-guided, biologically informed treatment planning. Its recommendations synthesize existing evidence and expert practice rather than new comparative clinical outcomes.